A detailed history of Morgan Stanley transactions in Savara Inc stock. As of the latest transaction made, Morgan Stanley holds 471,355 shares of SVRA stock, worth $1.48 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
471,355
Previous 257,325 83.17%
Holding current value
$1.48 Million
Previous $1.04 Million 92.67%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.96 - $5.07 $847,558 - $1.09 Million
214,030 Added 83.17%
471,355 $2 Million
Q2 2024

Oct 17, 2024

BUY
$3.66 - $5.34 $94,285 - $137,563
25,761 Added 11.12%
257,325 $1.04 Million
Q2 2024

Aug 14, 2024

BUY
$3.66 - $5.34 $94,285 - $137,563
25,761 Added 11.12%
257,325 $1.04 Million
Q1 2024

Oct 17, 2024

SELL
$4.19 - $5.59 $107,938 - $144,003
-25,761 Reduced 10.01%
231,564 $1.15 Million
Q1 2024

Aug 16, 2024

BUY
$4.19 - $5.59 $42,126 - $56,201
10,054 Added 4.54%
231,564 $1.15 Million
Q1 2024

May 15, 2024

BUY
$4.19 - $5.59 $42,126 - $56,201
10,054 Added 4.54%
231,564 $1.15 Million
Q4 2023

Aug 16, 2024

SELL
$3.18 - $4.9 $113,891 - $175,493
-35,815 Reduced 13.92%
221,510 $1.04 Million
Q4 2023

Feb 13, 2024

BUY
$3.18 - $4.9 $462,957 - $713,361
145,584 Added 191.74%
221,510 $1.04 Million
Q3 2023

Nov 15, 2023

SELL
$2.97 - $3.88 $86,943 - $113,583
-29,274 Reduced 27.83%
75,926 $287,000
Q2 2023

Aug 14, 2023

SELL
$1.69 - $3.24 $148,256 - $284,232
-87,726 Reduced 45.47%
105,200 $335,000
Q1 2023

May 15, 2023

SELL
$1.6 - $2.82 $42,123 - $74,242
-26,327 Reduced 12.01%
192,926 $376,000
Q4 2022

Feb 14, 2023

BUY
$1.11 - $1.64 $31,004 - $45,808
27,932 Added 14.6%
219,253 $339,000
Q3 2022

Nov 14, 2022

BUY
$1.36 - $1.88 $11,108 - $15,355
8,168 Added 4.46%
191,321 $298,000
Q2 2022

Oct 27, 2022

SELL
$1.1 - $1.58 $24,357 - $34,985
-22,143 Reduced 10.79%
183,153 $278,000
Q2 2022

Aug 15, 2022

SELL
$1.1 - $1.58 $24,357 - $34,985
-22,143 Reduced 10.79%
183,153 $278,000
Q1 2022

Oct 27, 2022

BUY
$1.05 - $1.36 $23,250 - $30,114
22,143 Added 12.09%
205,296 $268,000
Q1 2022

May 13, 2022

SELL
$1.05 - $1.36 $120,475 - $156,045
-114,739 Reduced 35.85%
205,296 $268,000
Q4 2021

Feb 14, 2022

SELL
$1.04 - $1.34 $84,887 - $109,374
-81,623 Reduced 20.32%
320,035 $397,000
Q3 2021

Nov 15, 2021

BUY
$1.18 - $1.64 $473,956 - $658,719
401,658 New
401,658 $554,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $357M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.